Skip to content

The application of opioid-free anesthesia combined with ultrasound-guided cervical plexus block in thyroid tumor resection surgery

The application of opioid-free anesthesia combined with ultrasound-guided cervical plexus block in thyroid tumor resection surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099585
Enrollment
Unknown
Registered
2025-03-26
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid tumor

Interventions

Opioid-free anesthesia group:opioid-free anesthesia combined with ultrasound-guided cervical plexus block
Control group:Before anesthesia induction: normal saline was injected slowly, and the pumping time exceeded 10min
Anesthesia induction: etomidate 0.2mg/kg, Sufentanil 0.3-0.5µg/kg, cisatracurium 0.05mg/kg
Anesthetic maintenance: propofol 4 to 6mg/kg/h, remifentanil 3 to 120µg/kg/h, sevoflurane 1 to 2%

Sponsors

China Medical University First Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. ASA Classification: Class I-II patients; 2. Age: 18–60 years of age; 3. BMI: 18.5–30 kg/m²; 4. Patients with thyroid tumors scheduled for elective surgery.

Exclusion criteria

Exclusion criteria: 1. Patients with goiter causing tracheal compression or dyspnea; 2. Untreated or inadequately treated hyperthyroidism (thyrotoxicosis); 3. Poorly controlled or untreated hypertension (resting systolic/diastolic blood pressure >180/100 mmHg); 4. Severe diabetes; 5. Severe liver or kidney dysfunction (Child-Pugh Class C or requiring renal replacement therapy); 6. Coronary artery disease or severe heart failure (left ventricular ejection fraction <40%, second-degree or higher atrioventricular block, sick sinus syndrome, or severe bradycardia with heart rate <50 beats per minute); 7. History of gastrointestinal ulceration; 8. Patients with psychiatric or mental health disorders who are unable or unwilling to comply with the study; 9. Pregnant or breastfeeding women; 10. Chronic use of opioids, psychotropic medications, or alcoholism history; 11. Allergy to any drug used in this study or contraindications to its use; 12. Patients who decline to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Incidence of Postoperative Nausea and Vomiting;Intraoperative Hemodynamic Adverse Reaction Incidence Rate;Visual Analogue Scale Score;Quality of Recovery-15 Score;Surgeon-Assisted Anesthesia Quality Evaluation;

Secondary

MeasureTime frame
The rate of rescue analgesia was calculated;Time from PACU admission to extubation;Incidence of urinary retention;Incidence of intestinal paralysis;

Countries

China

Contacts

Public ContactCui Yong

China Medical University First Affiliated Hospital

ycui@cmu.edu.cn+86 135 0407 2633

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026